Treatment of implanted mammary tumors with recombinant vesicular stomatitis virus targeted to Her2/neu

No abstract is available for this paper.

• Publication year

  2007

• Venue

  International Journal of Cancer

• Publication date

  2007-07-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/ijc.22680PMID 17354238
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Rapid Adaptation of a Recombinant Vesicular Stomatitis Virus to a Targeted Cell Line

  2006cited by this paper
• Preferential targeting of vesicular stomatitis virus to breast cancer cells.

  2004cited by this paper
• Vesicular stomatitis virus expressing a chimeric Sindbis glycoprotein containing an Fc antibody binding domain targets to Her2/neu overexpressing breast cancer cells.

  2003cited by this paper
• Adoptive-cell-transfer therapy for the treatment of patients with cancer

  2003cited by this paper
• Oncolytic vesicular stomatitis virus for treatment of orthotopic hepatocellular carcinoma in immune-competent rats.

  2003cited by this paper
• Development of Recombinant Vesicular Stomatitis Viruses That Exploit Defects in Host Defense To Augment Specific Oncolytic Activity

  2003influential reference
• Broadening of Epitope Recognition During Immune Rejection of ErbB-2-Positive Tumor Prevents Growth of ErbB-2-Negative Tumor 1

  2003cited by this paper
• The oncolytic effect of recombinant vesicular stomatitis virus is enhanced by expression of the fusion cytosine deaminase/uracil phosphoribosyltransferase suicide gene.

  2003cited by this paper
• Cytolytic viruses as potential anti-cancer agents.

  2002cited by this paper
• Toward a New Generation of Conditionally Replicating Adenoviruses: Pairing Tumor Selectivity with Maximal Oncolysis

  2002cited by this paper
• Reovirus Oncolysis of Human Breast Cancer

  2002cited by this paper
• Genetically Engineered Vesicular Stomatitis Virus in Gene Therapy: Application for Treatment of Malignant Disease

  2002cited by this paper
• Phase i study of intravesical vaccinia virus as a vector for gene therapy of bladder cancer.

  2001cited by this paper
• Vaccination with Cytoplasmic ErbB-2 DNA Protects Mice from Mammary Tumor Growth Without Anti-ErbB-2 Antibody1

  2001cited by this paper
• Antibody-Directed Targeting of Retroviral Vectors via Cell Surface Antigens

  2001cited by this paper
• Single-Chain Antibody Displayed on a Recombinant Measles Virus Confers Entry through the Tumor-Associated Carcinoembryonic Antigen

  2001cited by this paper
• Oncolytic viruses as therapeutic agents

  2001cited by this paper
• Cancer gene and oncolytic virus therapy.

  2001cited by this paper
• Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial.

  2000cited by this paper
• Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus

  2000influential reference
• Intergeneric poliovirus recombinants for the treatment of malignant glioma.

  2000cited by this paper
• Recombinant Measles Viruses Efficiently Entering Cells through Targeted Receptors

  2000cited by this paper
• T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities.

  2000cited by this paper
• Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus

  1999cited by this paper
• Cell-specific targeting of Sindbis virus vectors displaying IgG-binding domains of protein A

  1997cited by this paper
• A single-chain bispecific Fv2 molecule produced in mammalian cells redirects lysis by activated CTL.

  1996cited by this paper
• Recombinant vesicular stomatitis viruses from DNA.

  1995cited by this paper
• Replicating vectors for cancer therapy: a question of strategy.

  1994cited by this paper
• Sindbis virus attachment: isolation and characterization of mutants with impaired binding to vertebrate cells

  1993cited by this paper
• Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice.

  1991cited by this paper
• Characterization of a specific kinase inhibitory factor produced by vaccinia virus which inhibits the interferon-induced protein kinase.

  1984cited by this paper
• Characterization of the murine T cell surface molecule, designated L3T4, identified by monoclonal antibody GK1.5: similarity of L3T4 to the human Leu-3/T4 molecule.

  1983cited by this paper
• IgG or IgM monoclonal antibodies reactive with different determinants on the molecular complex bearing Lyt 2 antigen block T cell-mediated cytolysis in the absence of complement.

  1980cited by this paper

• Breaking Barriers: Animal Viruses as Oncolytic and Immunotherapeutic Agents for Human Cancers

  2024cites this paper
• Vesicular Stomatitis Virus (VSV) G Glycoprotein Can Be Modified to Create a Her2/Neu-Targeted VSV That Eliminates Large Implanted Mammary Tumors

  2023cites this paper
• Engineering Non-Human RNA Viruses for Cancer Therapy

  2023cites this paper
• Immunovirotherapy Based on Recombinant Vesicular Stomatitis Virus: Where Are We?

  2022cites this paper
• Reovirus-induced cell-mediated immunity for the treatment of multiple myeloma within the resistant bone marrow niche

  2021cites this paper
• A tool with many applications: vesicular stomatitis virus in research and medicine

  2020cites this paper
• Cytokines in oncolytic virotherapy.

  2020cites this paper
• Rhabdoviruses as vectors for vaccines and therapeutics.

  2020cites this paper
• Plasmacytoid dendritic cells orchestrate innate and adaptive anti-tumor immunity induced by oncolytic coxsackievirus A21

  2019cites this paper
• Therapeutic potency of oncolytic virotherapy in breast cancer targeting, current status and perspective

  2018cites this paper
• Envelope glycoproteins of vesiculoviruses : characteristics of antibody interactions and immunogenicity

  2018cites this paper
• Combining Oncolytic Viruses with Epigenetic Modifiers to Treat Acute Lymphocytic Leukemias

  2018cites this paper
• Oncotargeting by Vesicular Stomatitis Virus (VSV): Advances in Cancer Therapy

  2018cites this paper
• THE PRECLINICAL DEVELOPMENT OF ONCOLYTIC VIRAL IMMUNOTHERAPY FOR EPITHELIAL CANCER

  2017cites this paper
• Reovirus FAST Protein Enhances Vesicular Stomatitis Virus Oncolytic Virotherapy in Primary and Metastatic Tumor Models

  2017cites this paper
• Vesicular Stomatitis Virus is a Malleable Oncolytic Vector for the Treatment of Various Malignancies

  2017cites this paper
• Oncolytic Vesicular Stomatitis Virus as a Viro-Immunotherapy: Defeating Cancer with a “Hammer” and “Anvil”

  2017cites this paper
• Oncolytic Immunotherapy for Treatment of Cancer.

  2016cites this paper
• Murine Tumor Models for Oncolytic Rhabdo-Virotherapy.

  2016cites this paper
• Capitalizing on Cancer Specific Replication: Oncolytic Viruses as a Versatile Platform for the Enhancement of Cancer Immunotherapy Strategies

  2016influential citation
• DEVELOPING GENETICALLY ENGINEERED ONCOLYTIC VIRUSES FOR CANCER GENE THERAPY

  2015cites this paper
• Promising oncolytic agents for metastatic breast cancer treatment

  2015cites this paper
• Promising oncolytic agents for metastatic breast cancer treatment

  2015cites this paper
• Promising oncolytic agents for metastatic breast cancer treatment

  2015cites this paper
• Promising oncolytic agents for metastatic breast cancer treatment

  2015cites this paper
• Oncolytic potency of HER-2 retargeted VSV-FH hybrid viruses: the role of receptor ligand affinity

  2015cites this paper
• Promising oncolytic agents for metastatic breast cancer treatment

  2015cites this paper
• Mechanistic insights into the oncolytic activity of vesicular stomatitis virus in cancer immunotherapy

  2015cites this paper
• Memory Antitumor T-Cells Resist Inhibition by Immune Suppressor Cells.

  2015cites this paper
• High scFv-receptor affinity does not enhance the antitumor activity of HER2 retargeted measles virus

  2014cites this paper
• Going viral with cancer immunotherapy

  2014cites this paper
• NK cells in the tumor microenvironment.

  2014cites this paper
• Vesiculovirus Neutralization by Natural IgM and Complement

  2014cites this paper
• Evolution of oncolytic viruses: novel strategies for cancer treatment.

  2013cites this paper
• Preclinical Therapy of Disseminated HER-2+ Ovarian and Breast Carcinomas with a HER-2-Retargeted Oncolytic Herpesvirus

  2013cites this paper
• Development and characterization of a recombinant vesicular stomatitis virus (rvsv) for the treatment of glioblastoma

  2013cites this paper
• Understanding and altering cell tropism of vesicular stomatitis virus.

  2013cites this paper
• Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer.

  2012cites this paper
• Retargeting Vesicular Stomatitis Virus Using Measles Virus Envelope Glycoproteins

  2012cites this paper
• The molecular basis of herpesviruses as oncolytic agents.

  2012cites this paper
• Viral Immunotherapy to Eradicate Subclinical Brain Metastases

  2012cites this paper
• HERPESVIRUSES AS ONCOLYTIC AGENTS

  2012cites this paper
• Treatment with targeted Vesicular Stomatitis Virus generates therapeutic multifunctional anti-tumor memory CD4 T-cells

  2011cites this paper
• Oncolytic viruses: a step into cancer immunotherapy

  2011cites this paper
• Virus Adaptation and Treatment Oncolytic viruses : a step into cancer immunotherapy

  2011influential citation
• Oncolytic virotherapy of breast cancer.

  2011cites this paper
• Evaluation of an Attenuated Vesicular Stomatitis Virus Vector Expressing Interferon-β for Use in Malignant Pleural Mesothelioma: Heterogeneity in Interferon Responsiveness Defines Potential Efficacy

  2010cites this paper
• Interference of CD40L-Mediated Tumor Immunotherapy by Oncolytic Vesicular Stomatitis Virus

  2010cites this paper
• Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells

  2009cites this paper
• Recombinant vesicular stomatitis virus targeted to Her2/neu combined with anti-CTLA4 antibody eliminates implanted mammary tumors

  2009cites this paper
• AC133+ progenitor cells as gene delivery vehicle and cellular probe in subcutaneous tumor models: a preliminary study

  2009cites this paper
• Reverse Genetics of Measles Virus and Resulting Multivalent Recombinant Vaccines: Applications of Recombinant Measles Viruses

  2009cites this paper
• Natural and genetically engineered viral agents for oncolysis and gene therapy of human cancers

  2008cites this paper
• Basic science: (JULY 2007)

  2007cites this paper